Impact Biomedical IBO
NYSE IBO
$0.46 -0.03 (-7.15%)
As of: Sep 10, 2026 · 3:57 PM EDT

Impact Biomedical (IBO) Price to Sales (2025 - 2026)

Impact Biomedical's (IBO) quarterly Price to Sales came in at 16532.59 in Q2 2026, up 1361.12% on a YoY basis from 1131.5 in Q2 2025, and up 78.89% quarter-over-quarter from 9241.82 in Q1 2026.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Impact Biomedical (IBO) Price to Sales (2025 - 2026) Analysis & Trends

Impact Biomedical (IBO) has reported Price to Sales for 2 consecutive years, with 16532.59 the latest figure, recorded in Q2 2026.

Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Impact Biomedical 49.63 Mn 49.62 Mn 2,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 16,532.59
Mar 31, 2026 9,241.82
Sep 30, 2025 453.57
Jun 30, 2025 1,131.50